ONGOING INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
New York, New York--(Newsfile Corp. - June 14, 2024) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is investigating whether certain dir
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6
H.C. Wainwright analyst Emily Bodnar maintains $Ventyx Biosciences(VTYX.US)$ with a hold rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 39.3
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
New York, New York--(Newsfile Corp. - June 11, 2024) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is investigating whether certain dir
Ventyx Biosciences Insider Sellers Vindicated After 32% Drop
Insiders seem to have made the most of their holdings by selling US$222k worth of Ventyx Biosciences, Inc. (NASDAQ:VTYX) stock at an average sell price of US$2.44 during the past year. The company's
Daily options tracking | "Leader" live streaming is coming soon! Gamestop surged over 30% in pre-market, call options accounted for 70%.
Nvidia fell more than 1% overnight, and plummeted more than 3% at one point. There were nearly 2.25 million options traded, and the ratio of call options fell slightly to 60% on the options chain. The top three trades on the options chain were call options with expiry today and exercise prices of 1250, 1200, and 1300 US dollars respectively.
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Cuts Target Price to $10
Oppenheimer analyst Jeff Jones maintains $Ventyx Biosciences(VTYX.US)$ with a buy rating, and adjusts the target price from $12 to $10.According to TipRanks data, the analyst has a success rate of 40.
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results.G-III Apparel Group posted adjusted earn
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersVirax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37%
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Thursday.The Dow traded up 0.14% to 38,860.40 while the NASDAQ fell 0.07% to 17,175.73. The S&P 50
Ventyx Biosciences Is Maintained at Outperform by Oppenheimer
Ventyx Biosciences Is Maintained at Outperform by Oppenheimer
A Quick Look at Today's Ratings for Ventyx Biosciences(VTYX.US), With a Forecast Between $6 to $21
On Jun 06, major Wall Street analysts update their ratings for $Ventyx Biosciences(VTYX.US)$, with price targets ranging from $6 to $21.Wells Fargo analyst Derek Archila maintains with a buy rating, a
Express News | Ventyx Biosciences : Oppenheimer Cuts Target Price to $10 From $12
HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.
Ventyx Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/06/2024 12.15% HC Wainwright & Co. $6 → $6 Reiterates Neutral → Neutral 03/13/2024 180.37% Canaccord Ge
Ventyx Reports Preclinical Results for Anti-obesity Drug VTX3232
Express News | Ventyx Biosciences: Combination of GLP-1 receptor agonist Semaglutide with Vtx3232 showed improved efficacy compared to using Semaglutide/Vtx3232 alone for the primary endpoint.
Express News | Ventyx Biosciences:Additive Effects Seen for Vtx3232 Combined With GLP-1 Receptor Agonist Semaglutide Across Key Endpoints Vs Semaglutide/Vtx3232 Alone
Express News | Ventyx Biosciences Inc - Vtx3232 Demonstrated Improvements in Body Weight, Systemic Inflammatory Biomarkers & Cardiometabolic Parameters in Dio Mice
Express News | Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant Nlrp3 Inhibitor Vtx3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
The component stock Summit Therapeutics Plc. closed down 29.29% Intellia Therapeutics, Merus NV, and Sarepta Therapeutics fell 8.53%-8.21%; Moderna (Moderna) also fell 8.05%; Travere Therapeutics closed up 9.74%, Ventyx Biosciences rose 17.39% Agios Pharm
The component stock Summit Therapeutics Plc. closed down 29.29% Intellia Therapeutics, Merus NV, and Sarepta Therapeutics fell 8.53%-8.21%; Moderna (Moderna) also fell 8.05%; Travere Therapeutics closed up 9.74%, Ventyx Biosciences rose 17.39% Agios Pharmaceuticals up 23.21% A